Innovative MedTech fires CEO Merle Griff; faces $1.84M royalty lawsuit

AnTix Holdings, Inc.

CEO Merle Griff terminated April 18, 2024; Michael Friedman (President/CFO) appointed CEO.
Lawsuit filed April 17, 2024 by SarahCare shareholders alleging breach of contract for unpaid royalties.
Plaintiffs seek $1,841,537.01 in damages plus interest, costs, and attorney fees.
Company intends to vigorously defend the litigation.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Michael Friedman

Chief Executive Officer

AnTix Holdings, Inc.

Effective: 2024-04-18
Filed: April 22, 2024, 7:59 PM ET

and Michael Friedman, the Company’s President and CFO, was appointed as CEO of the Company.

Departed

Merle Griff

Chief Executive Officer

AnTix Holdings, Inc.

Effective: 2024-04-18
Successor: Michael Friedman
Filed: April 22, 2024, 7:59 PM ET

On April 18, 2024, Innovative MedTech, Inc. (the “Company”) terminated Merle Griff, PhD., as the Company’s CEO

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Friedman was appointed as Chief Executive Officer at AnTix Holdings, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

and Michael Friedman, the Company’s President and CFO, was appointed as CEO of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Merle Griff was terminated as Chief Executive Officer at AnTix Holdings, Inc..

Action: terminated
Role: Chief Executive Officer

Exact text from the filing

On April 18, 2024, Innovative MedTech, Inc. (the “Company”) terminated Merle Griff, PhD., as the Company’s CEO

View on SEC.gov

Source: SEC EDGAR

accession 0001477932-24-002284

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.